Literature DB >> 24032672

Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.

A Koop1, I Satzger, M Alter, A Kapp, A Hauschild, R Gutzmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24032672     DOI： 10.1111/bjd.12615

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  9 in total

Review 1.  Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series.

Authors:  Andrew J Dooley; Avinash Gupta; Madhumita Bhattacharyya; Mark R Middleton
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

Review 2.  Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.

Authors:  Kierstin Utter; Chloe Goldman; Sarah A Weiss; Richard L Shapiro; Russell S Berman; Melissa Ann Wilson; Anna C Pavlick; Iman Osman
Journal:  Oncology       Date:  2017-07-27       Impact factor: 2.935

Review 3.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Authors:  Sarah J Welsh; Pippa G Corrie
Journal:  Ther Adv Med Oncol       Date:  2015-03       Impact factor: 8.168

4.  MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Authors:  April A N Rose; Matthew G Annis; Dennie T Frederick; Marco Biondini; Zhifeng Dong; Lawrence Kwong; Lynda Chin; Tibor Keler; Thomas Hawthorne; Ian R Watson; Keith T Flaherty; Peter M Siegel
Journal:  Clin Cancer Res       Date:  2016-08-11       Impact factor: 12.531

5.  Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Authors:  Markus Hecht; Friedegund Meier; Lisa Zimmer; Bülent Polat; Carmen Loquai; Carsten Weishaupt; Andrea Forschner; Ralf Gutzmer; Jochen S Utikal; Simone M Goldinger; Michael Geier; Jessica C Hassel; Panagiotis Balermpas; Felix Kiecker; Ricarda Rauschenberg; Ursula Dietrich; Patrick Clemens; Carola Berking; Gerhard Grabenbauer; Dirk Schadendorf; Stephan Grabbe; Gerold Schuler; Rainer Fietkau; Luitpold V Distel; Lucie Heinzerling
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

6.  A systematic review of non-standard dosing of oral anticancer therapies.

Authors:  Faouzi Djebbari; Nicola Stoner; Verna Teresa Lavender
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

7.  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

Authors:  Monica Ceccon; Maria Elena Boggio Merlo; Luca Mologni; Teresa Poggio; Lydia M Varesio; Matteo Menotti; Silvia Bombelli; Roberta Rigolio; Andrea D Manazza; Filomena Di Giacomo; Chiara Ambrogio; Giovanni Giudici; Cesare Casati; Cristina Mastini; Mara Compagno; Suzanne D Turner; Carlo Gambacorti-Passerini; Roberto Chiarle; Claudia Voena
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

8.  Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma.

Authors:  Jie Shi; Bingyu Guo; Yu Zhang; Qiang Hui; Peng Chang; Kai Tao
Journal:  Biologics       Date:  2016-07-05

9.  Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Authors:  Sonya C Tate; Teresa F Burke; Daisy Hartman; Palaniappan Kulanthaivel; Richard P Beckmann; Damien M Cronier
Journal:  Br J Cancer       Date:  2016-03-15       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.